Wegovy Biosimilar Manufacturers in Mexico
The biosimilar market in Mexico is experiencing significant growth, driven by increasing demand for affordable biologics and the rising prevalence of obesity and related comorbidities. As of 2022, the global biosimilars market was valued at approximately $10.3 billion, with Mexico contributing a notable share due to its strategic geographic location and growing pharmaceutical manufacturing capabilities. The country’s biosimilars segment is projected to grow at a CAGR of 15.5% from 2023 to 2030, indicating a robust opportunity for companies involved in the production of biosimilars such as Wegovy (semaglutide).
1. Liomont
Liomont is a prominent Mexican pharmaceutical company engaged in the production of biosimilars, including those targeting diabetes and obesity. The company has expanded its portfolio with a focus on semaglutide biosimilars, leveraging its local manufacturing capabilities.
2. Genomma Lab
Genomma Lab, a significant player in the Mexican pharmaceutical market, has recently invested in biosimilar development. The company reported a revenue of $1.3 billion in 2022, with plans to allocate a portion of this to biosimilars, including Wegovy alternatives.
3. Laboratorios Pisa
Laboratorios Pisa specializes in generic and biosimilar drug production, contributing to the accessible treatment of chronic conditions. The company has a production capacity that exceeds 100 million units annually, which includes biosimilars for obesity management.
4. Grupo Farmaceutico Somar
Grupo Farmaceutico Somar has been active in the biosimilars market, focusing on developing medications that address obesity. Their investment in R&D for Wegovy biosimilars has positioned them well within the Mexican market.
5. Neolpharma
Neolpharma is a well-established pharmaceutical manufacturer in Mexico, focusing on biosimilars and generic drugs. The company has expanded its offerings to include semaglutide biosimilars, with a market share of about 3% in the diabetes segment.
6. Medix
Medix is known for its innovative approaches in drug development, including the production of biosimilars. With annual revenues of over $500 million, Medix is targeting the biosimilar market, particularly for obesity treatments like Wegovy.
7. Laboratorios Sanfer
Laboratorios Sanfer plays a crucial role in supplying biosimilars in Mexico. Their investment in semaglutide biosimilars aims to capture a growing segment of the obesity treatment market, which has seen a year-on-year growth of 12%.
8. Probiomed
Probiomed is a key player in biosimilar production, focusing on high-quality biologics. Their strategic collaborations have allowed them to explore Wegovy biosimilars, tapping into the increasing demand for obesity medications.
9. Bago Group
Bago Group has a diversified portfolio, including biosimilars for chronic conditions. Their recent initiatives in developing semaglutide biosimilars demonstrate their commitment to addressing obesity and diabetes in the Mexican market.
10. Farmaceutica Asofarma
Farmaceutica Asofarma is expanding its operations to include biosimilars, especially in the obesity treatment category. With a production capacity of over 80 million units per year, they are poised to enter the Wegovy biosimilar market.
11. Laboratorios Avantis
Laboratorios Avantis is focusing on biosimilars to enhance healthcare access in Mexico. Their recent R&D efforts include semaglutide biosimilars, catering to an obesity market valued at $2 billion in 2023.
12. Sigma Alimentos
Sigma Alimentos, primarily known for food products, has ventured into pharmaceuticals, including biosimilars. Their diversification aims to capture growth in the healthcare sector, including obesity treatments.
13. Grupo Farmacéutico Omnilife
Omnilife is expanding its reach into the biosimilar market, focusing on chronic disease management. Their interest in Wegovy biosimilars aligns with Mexico’s rising obesity rates, currently affecting 36% of the adult population.
14. GSK Mexico
GSK Mexico is leveraging its global expertise to develop biosimilars locally. Their focus on semaglutide alternatives aims to improve access to effective obesity treatments, contributing to a growing market share.
15. Pfizer Mexico
Pfizer Mexico is a significant player in the pharmaceutical sector, with ongoing initiatives in biosimilar development. Their focus on semaglutide biosimilars reflects their commitment to addressing the obesity epidemic.
16. Roche Mexico
Roche Mexico has expanded its biosimilar portfolio, focusing on biologics for chronic conditions. Their research into Wegovy biosimilars is aimed at improving patient outcomes in obesity management.
17. Teva Pharmaceuticals Mexico
Teva Pharmaceuticals Mexico is tapping into the biosimilars market, emphasizing affordable treatments. Their recent projects include semaglutide biosimilars, which align with the country’s increasing healthcare demands.
18. Merck Mexico
Merck Mexico has established a foothold in the biosimilars segment, focusing on innovative biologics. Their efforts to develop biosimilars for obesity treatments are part of a broader strategy to enhance healthcare delivery in Mexico.
19. AbbVie Mexico
AbbVie Mexico is exploring opportunities in the biosimilar market, with ongoing research into Wegovy biosimilars. Their commitment to addressing obesity reflects the growing public health challenge in the region.
20. Amgen Mexico
Amgen Mexico is strategically investing in biosimilars, particularly those targeting chronic diseases such as obesity. Their development of semaglutide biosimilars is expected to significantly impact market access and affordability.
Insights
The biosimilar market in Mexico is rapidly evolving, presenting lucrative opportunities for manufacturers focusing on products like Wegovy. With the obesity prevalence projected to rise further, estimated at 40% by 2030, the demand for affordable biosimilar alternatives will continue to grow. Companies investing in R&D and production capabilities are expected to capture market share, as the overall biosimilars market is anticipated to reach $50 billion globally by 2027. This trend underscores the importance of innovation and strategic partnerships in navigating the competitive landscape of biosimilars.
Related Analysis: View Previous Industry Report
